Regulatory PathRegulatory requirements compared

Active substances

Betamethasone + Salicylic acid

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
BETASAL OINTMENT30,5 mg,mgOintment · Topical1 TubeSAR 6.95Generic · PrescriptionBATTERJEE PHARMACETICAL FACTORYValid
DEFOSALIC LOTION20,0.5 mg,mgScalp solution · Topical1 BottleSAR 18.70Generic · PrescriptionDEEF PHARMACEUTICAL INDUSTRIESValid
DEFOSALIC OINTMENT30,0.5 mg,mgOintment · Topical1 TubeSAR 13.70Generic · PrescriptionDEEF PHARMACEUTICAL INDUSTRIESValid
DEFOSALIC OINTMENT30,0.5 mg,mgOintment · Topical1 TubeSAR 6.85Generic · PrescriptionDEEF PHARMACEUTICAL INDUSTRIESValid
DIPROSALIC OINTMENT30,0.5 mg/g,mg/gOintment · Topical1 TubeSAR 15.20NCE · PrescriptionOrganon BelgiumValid
SALIBET OINTMENT3,0.05 % (W/W),% (W/W)Ointment · Topical1 TubeSAR 14.40Generic · PrescriptionJamjoom Pharmaceuticals Factory CompanyValid
DIPROSALIC LOTION0.064, 2 %Lotion · Topical1 BottleSAR 18.70Generic · PrescriptionSCHERING-PLOUGHWithdrawn by MAH · Not Marketed
DIPROSALIC OINTMENT0.05, 3 %Ointment · Topical1 TubeSAR 22.85NCE · PrescriptionSCHERING-PLOUGHWithdrawn by MAH · Not Marketed
Indications — CHI Daman Drug Formulary

PSORIASIS

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
DIPROSALIC0057843630 MG / G; 0.5 MG / GOINTMENT · TOPICALORGANON CANADA INC.

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffBetamethasone dipropionate 0.05% / Salicylic acid 2% scalp application£10.10100 ml1 Oct 2026
NHS Drug TariffBetamethasone dipropionate 0.05% / Salicylic acid 3% ointment£3.1830 gram1 Oct 2026
NHS Drug TariffBetamethasone dipropionate 0.05% / Salicylic acid 3% ointment£9.14100 gram1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.